FDA Clearance Tracker · P130029
FLUENCY PLUS ENDOVASCULAR STENT GRAFT
Last checked: Nov 20, 2026Latest source record: Jun 17, 2014 (this decision)Source: openFDAMethods & limitations
Decided
Jun 17, 2014
Approved
Time to decision
182 days
Received Dec 17, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P130029
- Device name
- FLUENCY PLUS ENDOVASCULAR STENT GRAFT
- Applicant
- Bard Peripheral Vascular, Inc.
- Applicant location
- Tempe, AZ
- Received
- Dec 17, 2013
- Decided
- Jun 17, 2014
- Decision
- Approved
- Supplements
- 14 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE FLUENCY PLUS ENDOVASCULAR STENT GRAFT. THIS DEVICE IS INDICATED FOR USE IN THE TREATMENT OF IN-STENT RESTENOSIS IN THE VENOUS OUTFLOW OF HEMODIALYSIS PATIENTS DIALYZING BY EITHER AN ARTERIOVENOUS(AV) FISTULA OR AV GRAFT.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PFV. The earliest in FDA's data is P060002, decided Jul 23, 2007.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Bard Peripheral Vascular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250050 · Decided Sep 25, 2026 · 303 days after receipt
Device type: SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS (MIR) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.